314 related articles for article (PubMed ID: 33517237)
1. Osteosarcoma, personalized medicine, and tissue engineering; an overview of overlapping fields of research.
Bozorgi A; Sabouri L
Cancer Treat Res Commun; 2021; 27():100324. PubMed ID: 33517237
[TBL] [Abstract][Full Text] [Related]
2. The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma.
He L; Yang H; Huang J
BMC Cancer; 2021 May; 21(1):581. PubMed ID: 34016089
[TBL] [Abstract][Full Text] [Related]
3. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma cancer.
Liu R; Hu Y; Liu T; Wang Y
BMC Cancer; 2021 Dec; 21(1):1345. PubMed ID: 34922489
[TBL] [Abstract][Full Text] [Related]
4. A Hypoxia Gene-Based Signature to Predict the Survival and Affect the Tumor Immune Microenvironment of Osteosarcoma in Children.
Jiang F; Miao XL; Zhang XT; Yan F; Mao Y; Wu CY; Zhou GP
J Immunol Res; 2021; 2021():5523832. PubMed ID: 34337075
[TBL] [Abstract][Full Text] [Related]
5. Targeting autophagy is a promising therapeutic strategy to overcome chemoresistance and reduce metastasis in osteosarcoma.
Liao YX; Yu HY; Lv JY; Cai YR; Liu F; He ZM; He SS
Int J Oncol; 2019 Dec; 55(6):1213-1222. PubMed ID: 31638211
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.
Chen C; Xie L; Ren T; Huang Y; Xu J; Guo W
Cancer Lett; 2021 Mar; 500():1-10. PubMed ID: 33359211
[TBL] [Abstract][Full Text] [Related]
7. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
8. Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in osteosarcoma.
Jeddo SFA; Wei X; Li K; Li X; Yang Q; Dongol S; Li J
Oncol Rep; 2020 Sep; 44(3):1037-1048. PubMed ID: 32705239
[TBL] [Abstract][Full Text] [Related]
9. The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response.
Cascini C; Chiodoni C
Cells; 2021 Jul; 10(7):. PubMed ID: 34359840
[TBL] [Abstract][Full Text] [Related]
10. Applying Osteosarcoma Immunology to Understand Disease Progression and Assess Immunotherapeutic Response.
Pratt HG; Justin EM; Lindsey BA
Adv Exp Med Biol; 2020; 1258():91-109. PubMed ID: 32767236
[TBL] [Abstract][Full Text] [Related]
11. Osteosarcoma treatment: state of the art.
Ta HT; Dass CR; Choong PF; Dunstan DE
Cancer Metastasis Rev; 2009 Jun; 28(1-2):247-63. PubMed ID: 19214708
[TBL] [Abstract][Full Text] [Related]
12. Development of a Model System to Evaluate Local Recurrence in Osteosarcoma and Assessment of the Effects of Bone Morphogenetic Protein-2.
Geller DS; Singh MY; Zhang W; Gill J; Roth ME; Kim MY; Xie X; Singh CK; Dorfman HD; Villanueva-Siles E; Park A; Piperdi S; Gorlick R
Clin Cancer Res; 2015 Jul; 21(13):3003-12. PubMed ID: 25472999
[TBL] [Abstract][Full Text] [Related]
13. Construction of immune-related gene pairs signature to predict the overall survival of osteosarcoma patients.
Li LQ; Zhang LH; Zhang Y; Lu XC; Zhang Y; Liu YK; Khader MA; Jia-Wen ; Tao-Liu ; Li JZ
Aging (Albany NY); 2020 Nov; 12(22):22906-22926. PubMed ID: 33203792
[TBL] [Abstract][Full Text] [Related]
14. Scaffold-based 3D cellular models mimicking the heterogeneity of osteosarcoma stem cell niche.
Bassi G; Panseri S; Dozio SM; Sandri M; Campodoni E; Dapporto M; Sprio S; Tampieri A; Montesi M
Sci Rep; 2020 Dec; 10(1):22294. PubMed ID: 33339857
[TBL] [Abstract][Full Text] [Related]
15. Palliative therapy for osteosarcoma.
Errani C; Longhi A; Rossi G; Rimondi E; Biazzo A; Toscano A; Alì N; Ruggieri P; Alberghini M; Picci P; Bacci G; Mercuri M
Expert Rev Anticancer Ther; 2011 Feb; 11(2):217-27. PubMed ID: 21342041
[TBL] [Abstract][Full Text] [Related]
16. Comparative Immunology and Immunotherapy of Canine Osteosarcoma.
Mason NJ
Adv Exp Med Biol; 2020; 1258():199-221. PubMed ID: 32767244
[TBL] [Abstract][Full Text] [Related]
17. Humanization of bone and bone marrow in an orthotopic site reveals new potential therapeutic targets in osteosarcoma.
Wagner F; Holzapfel BM; McGovern JA; Shafiee A; Baldwin JG; Martine LC; Lahr CA; Wunner FM; Friis T; Bas O; Boxberg M; Prodinger PM; Shokoohmand A; Moi D; Mazzieri R; Loessner D; Hutmacher DW
Biomaterials; 2018 Jul; 171():230-246. PubMed ID: 29705656
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma.
Mu Y; Zhang H; Che L; Li K
Med Oncol; 2014 Feb; 31(2):821. PubMed ID: 24352761
[TBL] [Abstract][Full Text] [Related]
19. CBX2 is a functional target of miRNA let-7a and acts as a tumor promoter in osteosarcoma.
Han Q; Li C; Cao Y; Bao J; Li K; Song R; Chen X; Li J; Wu X
Cancer Med; 2019 Jul; 8(8):3981-3991. PubMed ID: 31150156
[TBL] [Abstract][Full Text] [Related]
20. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
J Immunother; 2015 Apr; 38(3):96-106. PubMed ID: 25751499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
